Background: Hepatocellular carcinoma (HCC) is one of the most common types of malignant tumour and has poor prognosis. Currently, systematic chemotherapy is the only approach to prolong survival. Thus the development of new treatment regimens is urgently needed to improve the therapeutic efficacy. Our study intended to assess the combination of dasatinib and irinotecan against HCC and made an effort to develop a potential medical choice for advanced HCC patients.
As one of the most common cancers, hepatocellular carcinoma (HCC) is the second cause of death by cancer and the overall median survival for HCC patients is o6 months currently (95% CI: 5.9-6.1; Njei et al, 2015; Torre et al, 2015) . Owing to the difficulty in accurate and reliable diagnosis of early-stage HCC, most patients are confirmed as advanced stage (Bruix et al, 2011) . For advanced HCC, the only first-line drug is sorafenib, which unfortunately has a limited effect on HCC. Therefore, a novel and effective clinical treatment strategy for HCC is urgently needed (Bupathi et al, 2015) .
Irinotecan, a kind of DNA Topoisomerase-I inhibitor, has been widely used as a first-line chemotherapy in some solid malignant tumours, such as colon cancer (Ottolino-Perry et al, 2015) . Numerous studies (Takeba et al, 2007) showed that SN38 (the in vivo active metabolite of irinotecan) had superior inhibition ability against HCC in vitro, whereas the phase II studies of irinotecan on HCC failed owing to its dose-dependent toxicity (O'Reilly et al, 2001 ). Consequently, a combination therapy with lower dose to decrease the toxicity of irinotecan will be a potential strategy for its application on HCC.
Dasatinib is a kind of tyrosine kinase inhibitor (TKI) targeted on Abl, c-kit and Src (Montero et al, 2011) and has been used to treat patients with Philadelphia chromosome-positive leukaemia (Talpaz et al, 2006) and several kinds of solid tumours (Mayer et al, 2011) . It has been reported that dasatinib combined with traditional chemotherapeutic agents could reveal additional antitumour effect (Milano et al, 2009; Secord et al, 2012; Somlo et al, 2013; Viktorsson et al, 2016) . The approaches in which dasatinib shows these effects are various. One of the mechanisms is decreasing protein biosynthesis through the modulation of target genes (Nunoda et al, 2007) .
As is well known, the overexpression caused by increased protein biosynthesis is one of the ways in which oncogenes are activated. In other words, the reduction of synthesis is a possible method to inhibit oncogenes. Polo-like kinase 1 (PLK1) is a wellstudied regulator in mitosis and has key role in numerous mitotic events (Barr et al, 2004) . It also directly takes part in DNA integrity maintenance and regulation of DNA repair according to accumulating evidence (Chabalier-Taste et al, 2016) . Of note, PLK1 is overexpressed in HCC (He et al, 2009 ) and has been proven to be one of the factors that could determine SN38 sensitivity of tumour cells (Zuco et al, 2015) . These facts indicate that the inhibition of PLK1 protein biosynthesis progress may confront the overexpression of PLK1 and consequently enhance the effect of SN38 on HCC. Here we hypothesised that dasatinib could interfere with PLK1 synthesis and show synergistic antitumour effect with SN38.
In this study, we confirmed that the combination of irinotecan and dasatinib has synergistic antitumour effect on HCC and exhibited that the synergistic effect was a result of inhibition of PLK1 through the downregulation of its synthesis and consequently induced increasing apoptosis of cancer cells. Therefore, the combination use of irinotecan and dasatinib might be an effective strategy for clinical therapy of HCC.
MATERIALS AND METHODS
Cell lines and cell culture. HepG-2 and BEL-7402, the human hepatocellular carcinoma cell lines, were purchased from Cell Bank of China Science (Shanghai, China). And cells were maintained in DMEM/RPMI-1640 containing 10% heat-inactivated fetal bovine serum (FBS) and 0.1% antibiotics at 37 1C in a humidified atmosphere with 5% CO 2 .
Drugs and reagents. Dasatinib was obtained from the first Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Irinotecan and SN38 were kindly provided by Dr Wei Lu (East China Normal University). Primary antibodies against GAPDH and ubiquitin HRP-labelled secondary antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Primary antibodies against cleaved PARP, cleaved caspase-3 and PLK1 were obtained from Cell Signaling Technology (Beverly, MA, USA). DMSO, sulphorhodamine B (SRB), Trichloroacetic acid, Tris base, propidium iodide (PI) and DAPI (4 0 , 6-diamidino-2-phenylindole) were obtained from Sigma-Aldrich (St Louis, MO, USA).
Cell proliferation assays. SRB colorimetric assay was applied to analyse cell proliferation (Vichai and Kirtikara, 2006) . Cells were plated in 96-well plates at a density of 4000 cells per well and left for 24 h growth in 5% CO 2 incubator at 37 1C. After exposed to different concentrations of dasatinib, SN38 or dasatinib combined with SN38 for 48 h, cells were fixed with 10% (wt/vol) trichloroacetic acid and stained with SRB for 30 min. SRB was dissolved in 10 mmol l À 1 Tris base for absorbance measurement using Multiskan Spectrum (Thermo Electron Corporation, Marietta, OH, USA) at 510 nm. And the inhibition rate of cell proliferation was calculated for each well as ((the absorbance of control cells À the absorbance of treated cells)/the absorbance of control cells) Â 100%.
Combination index (CI).
Based on the results of SRB colorimetric assay, CI value was calculated according to the Chou-Talalay method (Chou, 2010) using the CalcuSyn software (version 2; Biosoft, Cambridge, UK). It indicates synergistic, summation and antagonistic interaction between two drugs when CI values are o1.0, ¼ 1.0 and 41.0.
Colony-formation assay. HepG-2 or BEL-7402 cells were plated at 1000 per well in a six-well plate and treated with dasatinib and/ or SN38. Then, every 3 days, medium with 10% FBS were replaced and drugs were re-added. After 9 days of treatment, the cells were stained with a 0.1% crystal violet solution and photographed. The crystal violet was dissolved in 10% acetic acid and the absorbance values were detected at 595 nm.
Crystal violet was dissolved in 10% acetic acid and the absorbance values were determined at 595 nm. The clonogenic ability was calculated as ((the absorbance of treated cells À the absorbance of blank)/(the absorbance of control cells À the absorbance of blank)) Â 100%.
Flow cytometric assay. Flow cytometric assay was applied to detect apoptosis by Annexin V-FITC/PI apoptosis kit. HepG-2 and BEL-7402 cells were treated with dasatinib and/or SN38 for 48 h and harvested. Then cells were resuspended in 500 ml binding buffer and incubated with 5 ml of Annexin V-FITC and 5 ml of PI at room temperature for 15 min. Samples were then analysed on a FACS Calibur cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).
DAPI staining. In all, 2 Â 10 5 per well HepG-2 cells were cultured in a six-well plate and treated with dasatinib (80 nmol l À 1 ) and/or SN38 (20 nmol l À 1 ) for 48 h. And then all the cells were fixed with 4% paraformaldehyde for 30 min and permeabilised with PBS containing 0.1% Triton X-100. Cells were washed with PBS and stained with DAPI solution (1.0 mg ml À 1 ). Fluorescence was observed with Olympus Fluorview 1000 confocal microscope (Olympus Corporation, Tokyo, Japan).
Western blotting. HepG-2 and BEL-7402 cells were seeded in sixwell plates (2 Â 10 5 per well) and treated with dasatinib and/or SN38 for 48 h. After drug treatment, cells were harvested and resuspended in lysis buffer (50 mmol l À 1 Tris-HCl, 150 mmol l
NaCl, 2 mmol l À 1 EDTA, 2 mmol l À 1 EGTA, 25 mmol l À 1 NaF, 25 mmol l À 1 b-Sodium Glycerophosphate, 0.3% NP-40, 0.3% Triton X-100, 0.25% Leupeptin, 0.1% PMSF, 0.1% NaVO 3 ). Tumour tissue samples were sonicated in lysis buffer. All the samples were then centrifuged at 13 200 r.p.m. at 4 1C for 30 min. Protein samples were separated on Tris-glycine gels and transferred to nitrocellulose membrane and then incubated with corresponding HRP-linked antibody. Finally, protein bands were detected with the ECL-Plus Kit (PerkinElmer, MA, USA) and visualised on autoradiography film. 0 -GCACAUACCGCCU GAGUCU-3 0 ; #2: 5 0 -CCACCAAGGUUUUCGAUUG-3 0 ) and negative control siRNA (NC) were obtained from GenePharma Co. Ltd (Shanghai, China). HepG-2 cells (2 Â 10 5 per well) were seeded in a six-well plate and, after 24 h, siRNA were transfected with Oligofectamine2000 (Invitrogen, 12252-011), according to the manufacturer's instructions.
Real-time reverse transcription-PCR (qRT-PCR
Detection of treatment efficacy in vivo. In all, 5 Â 10 6 HepG-2 cells were injected subcutaneously to 24 female 5-6-week-old BALB/c mice. All the mice were randomly divided into four groups (control, treated with dasatinib, treated with irinotecan, treated with both dasatinib and irinotecan) when the tumour volume reached about 100 mm 3 . Dasatinib (100 mg kg À 1 , dissolved in 0.5% CMC-Na) was applied once daily and/or irinotecan (1 mg kg À 1 , dissolved in physiologic saline) was applied every 2 days for 30 days. Tumour volume (V) and body weight were measured every 2 days and the tumour volume (V) was calculated as V ¼ (length Â width 2 )/2. All animal experiments complied with the ARRIVE guidelines. The in vivo research carried out in the study titled 'Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1' was approved by Center for Drug Safety Evaluation and Research of Zhejiang University. The project number is P-IACUC-14-002.
Statistical analyses. All data are presented as mean ± s.d. Statistical significance were analysed by Student's t-test or oneway ANOVA analysis using SPSS 19.0 (IBM, New York, NY, USA) and differences were considered statistically significant when P valueo0.05.
RESULTS
Cytotoxicity of the combination of dasatinib and SN38 in human HCC cell lines. In our primary study, we assessed the antitumour effect of the combination of SN38 and dasatinib in human HCC cell lines, including HepG-2 and BEL-7402. Cells were treated with serial concentrations of SN38, dasatinib or both for 72 h, and SRB staining assay was used to detect the survival fractions of each treatment group. The survival curves of SN38, dasatinib and combination are shown in Figure 1A . The survival infractions were 55.8±6.2%, 50.9±4.1% and 20.8±4.9%, respectively, in HepG-2, when cells were exposed to SN38 (20 nM), dasatinib (80 nM) or combination. And those in BEL-7402 were 50.3 ± 5.0%, 55.6 ± 2.4% and 17.6 ± 4.9% respectively, when cells were exposed to SN38 (4 mM), dasatinib (10 mM) or combination, which suggested that the combination therapy between SN38 and dasatinib significantly reduced the survival fraction, compared with each agent alone. In order to verify the synergistic effect of dasatinib and SN38, CI values were calculated. As is shown in Figure 1B , the CI value of most combined concentration of dasatinib and SN38 are o0.9, which demonstrated the evident synergism of these two drugs on HepG-2 and BEL-7402.
To explore whether the combination treatment of SN38 and dasatinib can induce a long-term synergistic antitumour effect, we performed a clonogenic assay. HepG-2 and BEL-7402 cells were respectively treated with monotherapy or co-treatment for 24 h, and then cells in each group were normally cultured for clone formation at the same count. The typical pictures after 20-day culture are shown in Figure 1D , in which combination treatment resulted in a significant inhibition to the proliferation of HepG-2 and BEL-7402 cell clone while the monotreatment induced a moderate inhibition. Simultaneously, we calculated the rates of colony formation compared with the control group. Consistent with the picture, the HepG-2 colony-formation rates treated by dasatinib, SN38 and combination were 71.2 ± 10.3%, 57.9±6.6% and 11.1±1.7%, respectively. And the BEL-7402 colony-formation rates treated by dasatinib, SN38 and combination were 82.0±8.1%, 73.4±15.7% and 23.4±2.1%, respectively ( Figure 1E ), indicating that the combination treatment performed a long-term synergistic effect on the survival and proliferation of HCC cells. Taken together, combination of dasatinib and SN38 showed reinforced antitumour effect on human HCC cell lines in vitro.
The combination of SN38 and dasatinib results in enhanced caspase-dependent apoptosis in human HCC cell lines. In order to further confirm the synergistic antitumour effect, we then monitored the apoptosis of HepG-2 and BEL-7402 cells after 48-h exposure to SN38 (2 mM for BEL-7402 and 20 nM for HepG-2), dasatinib (5 mM for BEL-7402 and 80 nM for HepG-2) or both. The results detected by AV-PI staining using flow cytometry are shown in Figures 2A and B are shown in Figure 2C . In the combination group, extensive karyopyknosis and cellular fragmentation were observed (as indicated by the white arrows), while other treatments failed to arise the nucleus morphology alteration, which suggested that higher rate of apoptosis existed in the combination group.
As caspase-dependent pathway is an important pathway involved in cell apoptosis, we monitored the activation of the caspase cascade in HCC cells after the treatment with dasatinib and/or SN38 by western blotting analysis. It is known that cleaved PARP and cleaved caspase-3 represent occurrence of apoptosis (Jin and El-Deiry, 2005) . We found that dasatinib or SN38 were able to increase the cleavage of PARP and caspase-3 slightly, and these effect can be remarkably enhanced when applied together, which indicated that apoptosis was triggered by caspase cascades ( Figure 2D ). In sum, the above results proved that the combination use of dasatinib and SN38 led to increased apoptosis through caspase cascades in HCC cells, which finally caused more cell death.
Mitochondrial dysfunction-dependent apoptosis was involved in the combination of SN38 and dasatinib. Mitochondrial dysfunction is an important component of apoptosis, and notably mitochondrial membrane potential is one of the most significant events (Ly et al, 2003) . To explore the role of mitochondrial dysfunction in apoptosis induced by combination therapy of dasatinib and SN38, we applied flow cytometry with JC-1 staining to analyse mitochondrial dysfunction after 24 h treatment. As elucidated in Figures 3A and B, SN38 synergised with dasatinib gave rise to the decrease of mitochondrial membrane potential compared with single agent. The JC-1 green cells of the control, dasatinib, SN38 and combination groups in HepG-2 were 7.57, 11.77, 20.83 and 35.76%, respectively, and those in BEL-7402 were 17.15, 27.76, 26.04 and 70.88%, respectively.
In addition, Bcl-2 family had an important role in regulating the mitochondrial pathway of apoptosis (Martinou and Youle, 2011) . Bcl-2 was known to be an antiapoptotic protein and Bax was recognised as a pro-apoptotic protein (Brunelle and Letai, 2009 ). Inactivation of Bcl-2 and activation of Bax were obviously detected in HCC cells treated with both dasatinib and SN38 ( Figure 3C ), and it was demonstrated that Bcl-2 family were able to activate downstream apoptosis pathways, such as caspase activation, apoptosis and cell death (Danial and Korsmeyer, 2004) , which was consistent with our previous results. These data implicated that the combination therapy of dasatinib and SN38 induced mitochondrial related-apoptosis.
PLK1 is an important factor restricting antitumour effect of SN38 on HepG-2 cell line. As mentioned above, the anti-HCC efficacy of SN38 is limited due to dose-related side effects (O'Reilly et al, 2001) . We noticed that PLK1 is one of the determinants of tumour cell sensitivity to SN38 (Zuco et al, 2015) and could promote cell survival via blocking mitochondrial dysfunction (Matsumoto et al, 2009) . Assuming that PLK1 may have an important role in the limitation of SN38, we treated HepG-2 cells with SN38 at different concentrations and different periods of time. As a result, downregulation of PLK1 was observed and consistent with time or concentration gradients. However, the PLK1 inhibition induced by SN38 is not thorough under the concentrations and time periods of our experiments as shown in Figure 4A . At the same time, qRT-PCR results as shown in Figure 4B indicated that downregulation of PLK1 triggered by SN38 was highly possible to be a result of transcription inhibition. For validation of PLK1's role, we detected the relation between the inhibition rate of PLK1 and apoptosis in HepG-2 cells. As shown in Figure 4C , along with the downregulation of PLK1 by siRNA, cleaved PARP was increased obviously. And after we used different concentrations of PLK1 siRNAs to downregulate PLK1, as can be seen in Figure 4D , with more inhibition of PLK1, upraised cleaved PARP was detected by western blotting. Furthermore, when we silenced PLK1 in HepG-2 cells, the cleaved PARP level was further arisen ( Figure 4E ), and when PLK1 was overexpressed, the SN-38-induced cleaved PARP level was recovered ( Figure 4F ). These data implicated that PLK1 had a part in the limitation of SN38 and thoroughly downregulation of PLK1 might be a way to reinforce the efficacy of SN38 on HepG-2 cells.
PLK1 downregulation is a key segment of combination therapyinduced apoptosis in HepG-2 cells and was achieved by the inhibition of protein synthesis. As the role of PLK1 in SN38 sensitivity has been confirmed, we assumed that accelerated PLK1 downregulation by dasatinib may be the precise mechanism of the syngestic anticancer activity. After treatment by dasatinib in different concentrations and different periods of time, downregulation of PLK1 was observed and consistent with time or concentration gradients as shown in Figure 5A . Compared with dasatinib or SN38 monotherapy, combination treatment was able to reduce the level of PLK1 more thoroughly as shown in Figure 5B . These data indicated that dasatinib was able to downregulate PLK1 level in HepG-2 cells and led to synergistic effects. This was confirmed by PLK1 overexpression, which showed that, after PLK1 was overexpressed, the arisen cleaved PARP level and cell death induced by combination of dasatinib and SN38 was decreased ( Figures 5C and D) .
To further study how dasatinib enhanced PLK1 inhibition, we incubated HepG-2 cells with lysosomal inhibitors chloroquine (CQ, 10 mM) and proteasome inhibitor MG132 (2 mM) before combination treatment of SN38 (20 nM) and dasatinib (80 nM). Both CQ and MG132 had no effect on combination treatmentinduced suppression of PLK1, which denoted that degradation pathways were not involved in this combination therapy-induced PLK1 decrease ( Figure 5E) . Notably, the level of p-4EBP1 was observed to be reduced by combination treatment ( Figure 5B ), which implicated that the enhanced reduction of PLK1 might be a result of protein synthesis inhibition. For validation, CHX, an inhibitor of protein synthesis, was applied to prevent synthesis of PLK1 in HepG-2 cells as previously described (Liu et al, 2014) . We determined that combination treatment was unable to further reduce the level of PLK1 after CHX pretreatment, as shown in Figure 5F . In sum, the combination treatment of SN38 and dasatinib shows anti-HCC effect chiefly through downregulating PLK1 protein levels in the way of inhibiting protein synthesis.
The synergistic antitumour effect of dasatinib and irinotecan in HepG-2 xenografts. To further assess the synergistic antitumour effect of two agents, we detected the in vivo efficacy in HepG-2 xenograft nude mice models (n ¼ 6 per group). Dasatinib was administered i.g. at 100 mg kg À 1 once daily, and the i.p. administration of irinotecan at a dose of 1 mg kg À 1 every 2 days was conducted. As shown in Figure 6A , neither dasatinib (0.9077±0.0468 g) nor irinotecan (0.9757±0.1202 g) produced significant difference on the inhibition of tumour growth compared with that of the control group (1.0520±0.1196 g), while the combination of dasatinib and irinotecan robustly suppressed tumour growth and restrained tumour weight (0.5577±0.1101 g). As predicted, tumour volume and relative tumour volume were remarkably inhibited in the combination treatment group, showing a similar trend to the weight of tumour ( Figure 6B ). At the same time, no animal death or significant body weight change was observed in all groups during the experiments, which suggested that the combination therapy was well tolerated ( Figure 6C) .
In order to determine whether the synergistic antitumour effect was conducted by decreasing PLK1 and increasing tumour apoptosis in vivo, we detected the expression of apoptosis-related proteins and PLK1 in tumour tissues from xenograft mice. Consistent with our previous in vitro results, in vivo data showed that the cleavage of PARP and caspase-3 increased greatly in the combination treatment group, implying the activation of caspase cascades. Besides, the inhibition of PLK1 caused by irinotecan was reinforced by dasatinib ( Figure 6D ). In sum, these results demonstrated that dasatinib induced inhibition of PLK1 and enhanced the efficacy of irinotecan/SN38 in vivo, which consequently reduced the dose of SN38 to a relatively safe level in xenograft model.
DISCUSSION
HCC has a long history, and despite all the medical efforts, it still remains essentially incurable especially for advanced cases (Schutte et al, 2014; Tejeda-Maldonado et al, 2015) . One of the most important reasons of this unfavourable situation is the lack of efficient anti-HCC agents. In this work, we demonstrated that combination treatment of dasatinib and irinotecan/SN38 led to augmented antitumour effect on HCC both in vitro and in vivo. This effect relies on the inhibition of PLK1, which is enhanced by dasatinib through its effect on the protein synthesis progress.
PLK1 is a member of a serine/threonine kinases (PLK1-4) family and highly associated with G2 checkpoint (Lens et al, 2010; Liang et al, 2014) and is widely believed to have an important role Twenty-four hours after transfection with PLK1 expression plasmid or empty vector (PCMV6), HCC cells were treated with both 20 nM SN38 and 80 nM dasatinib for 48 h, and the inhibition of proliferation was observed by optical microscopy, while cleaved PARP and PLK1 were assessed by western blotting. Both cell death and c-PARP level were partially reversed. The reversed cell death was also confirmed by PI staining and flow cytometry. (E) HepG-2 cells were pretreated with CQ (10 mM) or MG132 (2 mM) for 2 h and then treated with both SN38 (20 nM) and dasatinib (80 nM) for 24 h, and the protein levels of PLK1 were measured by western blotting. (F) HepG2 cells were pretreated with both SN38 (20 nM) and dasatinib (80 nM) or not before exposing to CHX (10 mM) for different times, and PLK1 protein levels were detected by western blotting.
in cell proliferation (Raab et al, 2015) . The function of PLK1 could be related to various behaviours of tumour cells (Strebhardt and Ullrich, 2006) and thus the overexpression of PLK1 in HCC is often related to poor prognosis (He et al, 2009) . Based on the importance of PLK1, it is supposed to be a desirable target. In fact, PLK1 has proved to strongly influence SN38 sensitivity of tumour cells (Zuco et al, 2015) . Our data showed that SN38 did decrease the level of PLK1 in HCC cells but not thoroughly. The decrease was dependent on the concentration of SN38, which means if PLK1 could be inhibited by other methods, the concentration of SN38 could be lower to show effect. This might be a way to deal with the dose-dependent toxicity of irinotecan, which limits its effect on HCC. Dasatinib is a relatively well-studied antitumour agent. Its targets include a number of different molecules and pathways. PLK1 is not one of them, according to current perception. In fact, the relationship of PLK1 and dasatinib is almost unreported. However, the mechanism by which dasatinib influences certain downstream molecules remains heuristic. The way dasatinib acts on receptor tyrosine kinases such as c-kit and PDGFR is to block their kinase activity (Karaman et al, 2008) . Except decreasing activity, dasatinib can also downregulate the amount of some targets -often downstream proteins. Dasatinib is proved to induce apoptosis and cell cycle arrest in some kinds of tumour cells (Johnson et al, 2005) through the regulation of effectors molecules, such as p21, cyclin D1, CDK2 and CDK8. Among these, CDK2 and CDK8 are reported to be suppressed through gene modulation (Nunoda et al, 2007) . Which indicates that dasatinib is able to inhibit targets by downregulating their synthesis level, which is determined by gene expression.
According to the pattern in which dasatinib acts on CDK2 and CDK8 and the role of PLK1 in the antitumour effect of SN38, whether dasatinib could influence PLK1 by interfering with its synthesis is worth considering. This was confirmed by our data which showed that dasatinib could enhance the PLK1 inhibition of SN38 due to the blockage of protein synthesis. It is the first time that dasatinib is proved to have influence on PLK1. We also ruled out the possibility of dasatinib inhibiting PLK1 through protein degradation progress. The exact mechanism is likely to be a new direction of further study.
Of note, it is highly possible that the way in which dasatinib inhibits PLK1 differs from those of existing PLK1 inhibitors. Currently, there are a number of PLK1 inhibitors undergoing clinical trials such as Volasertib (Van den Bossche et al, 2016) and Rigosertib (Bowles et al, 2014; Garcia-Manero et al, 2016; O'Neil et al, 2016) , and whether they are ATP-binding competitive or not, these PLK1 inhibitors target on PLK1 kinase activity (Schoffski, 2009 ) instead of reducing its amount. This feature might limit the application range of the existing PLK1 inhibitors to some extent as not all tumours with high level of PLK1 expression necessarily show arisen kinase activity. In fact, the target diseases of current clinical trials of Volasertib and Rigosertib are quite restricted (Schoffski, 2009) compared with the wide range of PLK1 overexpression (Strebhardt, 2010) , and HCC is not included in the trials. Under this circumstance, the finding that dasatinib is able to inhibit protein synthesis of PLK1 presents a new method targeting on PLK1 and might have better universality especially on HCC. Apart from the restricted application range, existing PLK1 inhibitors also have to face potential problems about drug resistance. It is believed that one of the most common reasons why acquired resistance of inhibitors occurs is point mutation of the kinase domain (Daver et al, 2015) . Which means, compared with PLK1 inhibitors targeting on kinase activity, dasatinib will suffer less risk of developing acquired resistance, as its mechanism depends on protein synthesis instead of gene level or kinase structure.
Given to the close correlation of PLK1 and tumour cell proliferation, enhanced inhibition of PLK1 is naturally related to increased apoptosis (Bucur et al, 2013) . It was reported that mitochondria dysfunction could be involved in the progress from PLK1 inhibition to apoptosis (Matsumoto et al, 2009) . Consistent with these previous works, our study also revealed that the apoptosis rate of HCC cells was elevated as a result of PLK1 inhibition and mitochondria dysfunction, and a synergistic antitumour effect could be observed both in vitro and in vivo. In conclusion, PLK1 might be a potential target of dasatinib and the combination treatment of dasatinib and irinotecan/SN38 led to augmented inhibition of PLK1, which subsequently enhanced irinotecan/SN38-induced mitochondrial pathway of apoptosis. This study presented a promising synergistic antitumour efficacy of a traditional cytotoxic drug and a TKI for HCC and may hopefully inspire novel therapies for the disease.
